Corium International Inc. (NASDAQ:CORI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Friday.
According to Zacks, “Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. “
A number of other brokerages have also weighed in on CORI. FBR & Co set a $18.00 target price on Corium International and gave the company a “buy” rating in a research note on Friday, August 5th. Leerink Swann set a $16.00 target price on Corium International and gave the company a “buy” rating in a research note on Tuesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Corium International in a research note on Monday, September 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $12.25.
Shares of Corium International (NASDAQ:CORI) traded up 17.23% during trading on Friday, hitting $5.51. The stock had a trading volume of 55,021 shares. The company’s market capitalization is $122.36 million. Corium International has a 1-year low of $3.14 and a 1-year high of $9.93. The firm has a 50 day moving average of $5.02 and a 200 day moving average of $4.72.
A number of institutional investors have recently bought and sold shares of the stock. Paloma Partners Management Co purchased a new position in Corium International during the second quarter valued at about $152,000. Opaleye Management Inc. boosted its position in Corium International by 1.4% in the first quarter. Opaleye Management Inc. now owns 360,000 shares of the biopharmaceutical company’s stock valued at $1,390,000 after buying an additional 5,000 shares in the last quarter. Finally, RTW Investments LLC boosted its position in Corium International by 3.0% in the second quarter. RTW Investments LLC now owns 852,961 shares of the biopharmaceutical company’s stock valued at $2,960,000 after buying an additional 24,629 shares in the last quarter. Institutional investors and hedge funds own 88.35% of the company’s stock.
About Corium International
Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.